TIZIANA LIFE SCIENCES LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8099 USD | +9.34% |
|
+8.86% | +44.62% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 93.41 | 60.66 | 56.17 |
| Enterprise Value (EV) 2 | 51.23 | 42.91 | 55.24 |
| P/E ratio | -4.01 x | -3.95 x | -3.29 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -1.87 x | -2.94 x | -3.07 x |
| EV / FCF | -3.83 x | -5.41 x | -4.9 x |
| FCF Yield | -26.1% | -18.5% | -20.4% |
| Price to Book | 2.38 x | 3.08 x | 10.4 x |
| Nbr of stocks (in thousands) | 97,306 | 101,360 | 100,308 |
| Reference price 3 | 0.9600 | 0.5985 | 0.5600 |
| Announcement Date | 5/23/22 | 4/26/23 | 5/10/24 |
1USD in Million2GBP in Million3USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -7.433 | -9.916 | -30.4 | -27.37 | -14.58 | -17.98 |
| EBIT 1 | -7.445 | -9.921 | -30.41 | -27.37 | -14.59 | -17.98 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.454 | -10.01 | -28.34 | -26.66 | -15.4 | -17.24 |
| Net income 1 | -5.995 | -9.323 | -26.13 | -23.42 | -15.4 | -17.69 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.0470 | -0.0683 | -0.1546 | -0.2391 | -0.1517 | -0.1700 |
| Free Cash Flow 1 | -1.972 | -3.663 | -2.577 | -13.38 | -7.931 | -11.28 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/4/19 | 6/17/20 | 5/17/21 | 5/23/22 | 4/26/23 | 5/10/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.62 | - | - | - | - |
| Net Cash position 1 | 3.92 | - | 65.3 | 42.2 | 17.8 | 0.94 |
| Leverage (Debt/EBITDA) | - | -0.0625 x | - | - | - | - |
| Free Cash Flow 1 | -1.97 | -3.66 | -2.58 | -13.4 | -7.93 | -11.3 |
| ROE (net income / shareholders' equity) | 943% | 373% | -91.9% | -45.2% | -50.6% | -141% |
| ROA (Net income/ Total Assets) | -128% | -133% | -52% | -28.6% | -24.2% | -58.1% |
| Assets 1 | 4.681 | 6.99 | 50.21 | 81.77 | 63.59 | 30.42 |
| Book Value Per Share 2 | 0 | -0.0400 | 0.3200 | 0.4000 | 0.1900 | 0.0500 |
| Cash Flow per Share 2 | 0.0300 | 0 | 0.3400 | 0.4100 | 0.1800 | 0.0100 |
| Capex | - | 0 | 0 | 0.02 | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/4/19 | 6/17/20 | 5/17/21 | 5/23/22 | 4/26/23 | 5/10/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +44.62% | 74.3M | |
| +67.53% | 62.86B | |
| -0.77% | 41.38B | |
| +45.66% | 40.38B | |
| -10.72% | 27.64B | |
| +13.30% | 26.46B | |
| -22.79% | 18.9B | |
| +4.70% | 12.67B | |
| +24.10% | 12.27B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- TLSA Stock
- Financials Tiziana Life Sciences Ltd
